Spasticity …

General Neurology

Updated 10.26.2023
Released 08.14.1998
Expires For CME 10.26.2026

Spasticity

Authors: Hannah Aura Shoval MD, Kimberly Heckert MD, Elaine Hatch MD

See Contributor Disclosures

Editor: Bernard L Maria MD

Spasticity

In This Article

Quick Link

Introduction

Overview

Spasticity is a common debilitating factor in central nervous system disorders characterized by velocity-dependent resistance to movement. There are many established treatments, such as oral medications (ie, baclofen, valium), toxin injections, nerve blocks, intrathecal baclofen pumps, and selective dorsal rhizotomy. When carefully selected based on a patient's condition and goals, these treatments can greatly improve function and quality of life and prevent secondary complications. A combination of the above treatments is usually needed for optimal results. In addition to well-established treatments, new and promising treatments include stem cell treatments, hyaluronidase, vibration, extracorporeal shock wave therapy, and cryo-neurolysis.

Key points

	• Early diagnosis and treatment of spasticity is critical for best outcomes, including preventing soft-tissue contractures and bony subluxation, dislocation, and deformities.
	• Treatment of spasticity is generally multimodal, including a combination of treatments, must be personalized to the individual, and may change over time.
	• Clear functional and quality-of-life goals are necessary to ensure optimal outcomes.

Historical note and terminology

Spasticity, derived from the Greek word “spastikos” or Latin “spasticus,” which means to pull (16), is a condition that can result from any central nervous system insult.

The most widely accepted definition of spasticity is a motor disorder characterized by a velocity-dependent increase in tonic stretch reﬂexes with exaggerated tendon reﬂexes, resulting from hyperexcitability of the stretch reﬂex (38). Despite wide acceptance, those who diagnose and manage spasticity can attest that Lance’s definition is not exhaustive of the array of spasticity presentations. These vary broadly and may be influenced by several factors, including the mechanism and severity of the insult, age of onset, and other factors. Young further added characteristics of positive and negative symptoms. Positive symptoms include exaggerated cutaneous reflexes, including nociceptive and flexor withdrawal reflexes, autonomic hyperreflexia, dystonia, and contractures. Negative symptoms include paresis, lack of dexterity, and fatigability (76).

Treatment for spasticity was documented as early as the late 19th century when surgeons Abbe and Bennet discussed decreasing tone in a spastic limb through sensory rhizotomies. Later, in 1898, scientist Sherrington published experiments in which the sensory roots of spastic cats were severed to relieve spasticity (01). The technique of sensory rhizotomies has been improved and continues to be used today as a treatment for patients with spasticity, as does neuromuscular blockage, a longstanding treatment that has been used for over 30 years (36).

Today, there are comprehensive pharmacologic and nonpharmacologic spasticity treatments widely available, including stretching and therapeutic modalities, oral therapy, chemodenervation with neurotoxin, chemoneurolysis with phenol or ethyl alcohol, intrathecal baclofen, and additional surgeries, such as tendon lengthening or transfers and functional neurotomy. There are also new and emerging therapies, including cryoneurolysis and injection of hyaluronidase. These are discussed in more detail in the treatment section.

Clinical manifestations

Presentation and course

Spasticity is a common symptom of upper motor neuron disease. It can be seen in various conditions affecting the central nervous system, including cerebral palsy, stroke, traumatic brain injury, multiple sclerosis, and spinal cord injury. Spasticity can manifest in various ways in terms of location and severity due to this variation in etiology and localization.

Spasticity is assessed by attempts to measure resistance to passive movement. The most commonly used assessments of passive movement are the Modified Ashworth Scale (05) and the Tardieu Scale (67). The Modified Ashworth Scale grades spasticity on a scale from 0 to 4 (03). A joint is passively moved, testing the corresponding muscle’s resistance to stretch and where the resistance is felt in the range of motion. In cases of mild spasticity, the muscles will only resist when stretched at a higher velocity. In the case of severe spasticity, movement of the muscle may be difficult to impossible (12). The Tardieu Scale also assesses resistance to passive movement but notes an angle at which the catch is appreciated and compares the angles when the muscle is stretched at different velocities. It also factors clonus into the assessment.

Table 1. The Modified Ashworth Scale

Grade	Description
0	No increase in muscle tone.
1	Slight increase in muscle tone, manifested by a catch and release or by minimal resistance at the end of the range of motion when the affected part(s) is moved in flexion or extension.
1+	Slight increase in muscle tone, manifested by a catch, followed by minimal resistance throughout the remainder (less than half) of the range of motion.
2	More marked increase in muscle tone throughout most of the range of motion, but affected part(s) are easily moved.
3	Considerable increase in muscle tone; passive movement is difficult.
4	Affected part(s) are rigid in flexion or extension.
(05).

Table 2. Tardieu scale

Velocities
	V1	As slow as possible, slower than the natural drop of the limb segment under gravity
	V2	Speed of limb segment falling under gravity
	V3	As fast as possible, faster than the rate of the natural drop of the limb segment under gravity
Scoring
	0	No resistance throughout the course of the passive movement
	1	Slight resistance throughout the course of passive movement, no clear catch at a precise angle
	2	Clear catch at a precise angle, interrupting the passive movement, followed by release
	3	Fatigable clonus with less than 10 seconds when maintaining the pressure and appearing at the precise angle
	4	Unfatigable clonus with more than 10 seconds when maintaining the pressure and appearing at a precise angle
	5	Joint is immovable
(67; 30)

The examination can begin with the patient relaxed and lying down, with the head in a neutral position and arms resting to the sides. It can be easier to determine the extent of spasticity in this position. Observing a patient’s level of function, such as movement of limbs, standing, or walking, can be especially valuable, and video cameras can assist in providing more objective comparisons of movement and function before and after treatment.

The amount of function the patient derives from spasticity can be evaluated by doing a functional examination and testing motor strength and control. It is essential to evaluate the advantages and disadvantages that spasticity in individual muscles gives the patient so that treatment strategies and goals can be identified. Disadvantages of spasticity may include interference with activities of daily living, inhibition of good sleep, contractures, dislocations, skin breakdown, bowel and bladder dysfunction, impairment of respiratory function, pain with stretching, and masking of the return of voluntary movement. However, given that many people with spasticity have underlying weakness and decreased motor control, patients may rely on a certain amount of spasticity for maintaining muscle tone and managing activities of daily living.

Related clinical manifestations should also be evaluated, such as resistance to passive stretch, decreased range of motion, increased deep tendon reflexes, positive Babinski sign, or a more subtle reduction of the plantar withdrawal reflex. Motoneuronal overactivity, or overflow movement, where input to motoneurons produces excessive and prolonged muscle activity and contractions of many limb muscles, can also be observed (79). Reduction in the tonic vibration reflex can also be tested.

Prognosis and complications

Spasticity results in limited functional capacity and increased inactivity. The sequelae of this inactivity may include decubiti, cardiovascular problems, thrombophlebitis, respiratory infections, fixed contractures, osteoporosis, bladder and bowel problems, and social isolation. Ultimately, these consequences of inactivity may lead to a further decrease in strength and function (19). The patient’s quality of life may be compromised as spasticity negatively impacts mobility, hygiene, self-care, sleeping patterns, self-esteem, mood, and sexual function.

Early treatment of spasticity and preventative measures can help to prevent many of these complications.

Clinical vignette

Patient A. Patient A was a 5-year-old African-American boy with a history of developmental delay and a diagnosis of cerebral palsy of the spastic-diplegic type. He first presented at 18 months with severe spasticity in both lower extremities. The patient walked on tiptoes and had hip and knee flexion. There was some scissoring of the legs. On examination, exaggerated deep tendon reflexes were elicited, as were sustained clonus and bilateral Babinski signs. Brain MRI showed findings that may be secondary to previous hypoxic injury, compatible with cerebral palsy. Prior treatments included physical therapy, bilateral ankle-foot orthosis, serial casting, and oral baclofen. Before treatment with botulinum toxin injections, the patient was a tiptoe walker.

Spasticity before botulinum toxin injection

This boy with spastic-diplegic cerebral palsy walked on tiptoes until treatment with botulinum toxin injections. (Contributed by Dr. Yasser Awaad.)

With treatment the patient’s gait has improved; he is flat-footed and presently wears bilateral ankle-foot orthosis.

Spasticity after botulinum toxin injection

After treatment with botulinum toxin injection, this boy's gait has improved, he is flat-footed, and he wears ankle-foot orthosis. (Contributed by Dr. Yasser Awaad.)

His hygiene and positioning have also improved and he returns every 6 to 9 months for reinjection.

Patient B. Patient B was a 7-year-old African-American boy with a history of cerebral palsy of the spastic-diplegic type. On primary examination, he presented with tightness of both hamstrings and heel cords, in the right more involved than the left. The patient had good toe standing, especially on the right side, and good sitting balance with a kyphotic sacral-type sitting due to the tight hamstring. He uses a walker to ambulate and walks on tiptoes. The EEG was abnormal, indicating the presence of epileptiform activity from the left central parietal head region and diffuse background disorganization, which indicates underlying neuronal dysfunction. Treatments before intrathecal baclofen pump implantation included bilateral ankle-foot orthoses, tendon releases, alcohol block, and botulinum toxin injections. Before treatment with intrathecal baclofen, the patient was dependent on a caregiver and used a walker to ambulate.

Spasticity before intrathecal baclofen treatment

This boy with spastic-diplegic cerebral palsy walked on tiptoes and used a walker to ambulate until treatment with intrathecal baclofen. (Contributed by Dr. Yasser Awaad.)

With the intrathecal baclofen pump, the patient has gained function, does not use a walker to ambulate, and performs activities of daily living independently.

Spasticity after intrathecal baclofen treatment

With the intrathecal baclofen pump the patient has gained function, does not use a walker to ambulate, and successfully performs activities of daily living. (Contributed by Dr. Yasser Awaad.)

Patient C. Patient C was a 61-year-old man with a history of chronic cerebrovascular accident with left spastic hemiparesis. He was ambulatory with the use of an ankle foot orthosis and used his left hand as a holder for activities of daily living. The patient had never received prior treatment for spasticity and presented due to stiffness contributing to low back pain. On primary examination, fingers were flexed with hypertonia, worst at proximal interphalangeal and metacarpophalangeal joints. Ambulation revealed a stiff knee gait with reduced passive dorsiflexion of the ankle, worse with knee extension. Standing elicited toe flexion and tenderness in the lumbar paraspinals. The patient’s goal was to reduce back stiffness and enhance the functional use of his hand. The treatment plan included physical and occupational therapy, oral therapy, and chemodenervation. He was started on oral tizanidine and received botulinum toxin injection in the finger flexors, hand intrinsics, ankle plantar flexors, and toe flexors. Following these interventions, the patient had improved hand function and reduced knee stiffness. Back pain began resolving with tizanidine and continued to improve as gait became less effortful. With physical, oral, and focal therapies, he could take longer walks with his wife and increase the ease of performing activities of daily living.

Biological basis

Etiology and pathogenesis

Spasticity may result from diffuse or localized pathology of the cerebral cortex, brainstem, or spinal cord. Possible causes of such injuries include cerebral palsy, traumatic brain injury, stroke, multiple sclerosis, spinal cord trauma, or diseases such as genetic neurodegenerative disorders and anoxic insults. The neurologic localization of the lesion causing spasticity may result in different clinical manifestations. Thus, it is essential to consider whether the spasticity results from cerebral or spinal cord pathology and whether it is diffuse or localized.

Diffuse cerebral injury or diseases would include anoxia or toxic or metabolic encephalopathies, whereas localized cerebral injury would include tumors, abscesses, cysts, arteriovenous malformations, cystic degeneration of the brain, hemorrhage, or trauma. Causes of cerebral palsy include generalized hypoxic ischemic injuria and anoxia or localized periventricular leukomalacia, encephalomalacia, and cortical abnormalities, such as porencephaly or congenital malformations of gyri (eg, micropolygyria). Spinal cord injury or disease caused by trauma, inflammatory or demyelinating disease, degenerative disorders, or compression such as is caused by a tumor or cyst (12; 21; 03) are also causes of spasticity but are less common than cortical causes.

Because of this, more than one mechanism may be responsible for the disturbance in muscle tone, and the mechanisms may vary between patients. The neuropathophysiologic processes involved in spasticity are complex and not fully understood. Still, there is a widely accepted hypothesis that spasticity depends on hyperexcitability of spinal alpha motor neurons, which is due to the interruption of descending modulatory influences carried by the corticospinal, vestibulospinal, and reticulospinal tracts and other possible tracts (18). Ia afferent fibers provide segmental input from muscle spindles to alpha motor neuron pools. They synapse on segmental inhibitory interneurons that then inhibit alpha motor neurons innervating antagonist muscles in the Ia reciprocal inhibition pathway. Ib afferents inhibit alpha motor neurons through the Golgi tendon organs via the Ib inhibitory interneuron in another pathway known as nonreciprocal inhibition (76; 18). Increased excitation of these afferents does not seem to be the cause of spasticity. Instead, evidence supports that reduced reciprocal inhibition of antagonist motor neuron pools by Ia afferents, decreased presynaptic inhibition of Ia afferents, and decreased nonreciprocal inhibition by Ib terminals are all possible pathophysiologic mechanisms of spasticity (76). The pathophysiology of traumatic brain injury involves a complex combination of forces that has been a subject of substantial debate (14).

Prevention

Spasticity can occur from any CNS trauma or insult. In the case of CNS trauma, safety precautions, such as helmets and seatbelts, are advised. Safety measures should be taken in individuals with conditions that make them susceptible to brain or spinal cord injury or both (ie, helmets for patients with frequent seizures).

To prevent cerebral palsy and the resulting spasticity in infants, mothers must receive prenatal care during pregnancy, measures must be taken to avoid premature labor, and special consideration should be given to pregnancies involving multiple gestations. When appropriate, antenatal magnesium sulfate and corticosteroids (64), neonatal use of caffeine, and hypothermia (63), as well as early resuscitation and access to acute care can help with risk factors for cerebral palsy. When combined with therapies, umbilical cord blood has been shown to improve motor skills over therapies alone (51). There is increasing evidence for erythropoietin's effects on neuroregeneration (63).

Noxious stimuli, such as constipation, urinary retention, infection, or sources of pain, all relatively common in this patient population, can worsen underlying spasticity. It is recommended to monitor changes in spasticity and address any underlying causes of worsening spasticity.

To prevent or minimize secondary complications of spasticity, including contractures, nerve entrapment, and skin breakdown, treatment of problematic spasticity should be initiated on recognition. Ongoing clinical reassessment is critical to ensure that treatment efforts are maximized. Early and frequent range of motion in a paretic limb and using splints for positioning can also help prevent skin breakdown and contracture.

Differential diagnosis

Confusing conditions

Conditions that are sometimes confused with spasticity and can co-occur with spasticity include:

Rigidity. In rigidity, a generalized high tone throughout a joint range of motion is not velocity-dependent. Rigidity is also more likely to relax through repeated stretching (12; 76).

Volitional movement. Purposeful movement (eg, purposeful resistance to movement) can include guarding or tensing a muscle due to anxiety, pain, or fear of pain. This can cause resistance to movement and may even appear to be velocity-dependent as greater velocity may elicit more pain/fear of pain and, thus, more purposeful resistance. In children, this can also be due to resisting the examiner, not wanting to participate in the examination, or not understanding how to relax muscles.

Dystonia. In dystonia, an involuntary pattern of muscle contractures leads to repetitive movement and abnormal posturing.

Contracture. In contracture, a joint is fixed due to muscle, ligament, tendon, and skin tightening and cannot be moved.

Associated or underlying disorders

Spasticity is due to injury to the upper motor neuron unit and can develop in many neurologic disorders. Associated conditions depend on the underlying neurologic diagnosis and may include deep vein thrombosis, heterotopic ossification, and autonomic dysreflexia, which can be severe and potentially life-threatening (13; 11). Many orthopedic problems may result from a spastic limb, including spontaneous fracture, dislocation of the hip or knee, heterotopic ossification, and scoliosis. Spasticity can also cause impingement of peripheral nerves, for example, causing cubital or carpal tunnel syndrome.

Because children are still growing, those with spasticity due to any cause are at high risk for bony deformity, including increased risk for hip subluxation or dislocation (which can result in pain and prevent sitting or standing) as well as scoliosis (which can cause restrictive lung disease). Vigilance in treating spasticity in children is, thus, especially critical, and close hip surveillance, including x-rays, is critical as physical examimation alone can not reliably identify hip subluxation. For children with cerebral palsy, there are specific guidelines; one of the most established in the United States is that published by the American Academy of Cerebral Palsy and Developmental Medicine: https://www.aacpdm.org/publications/care-pathways/hip-surveillance-in-cerebral-palsy.

Diagnostic workup

Spasticity is a clinical diagnosis of velocity-dependent resistance to movement due to a neurologic cause. When clinically identified, testing can be done to establish the underlying cause, such as any lesions of brain or spinal cord injury. History and physical examination are used to help localize the lesion and guide further workup, which most commonly includes MRI of the brain or spine or genetic studies.

Signs of spasticity can also be seen in EMG or nerve conduction studies. On EMG, the jerks show greater amplitudes than are normal and are followed by after-discharge of the motor units that is often slightly longer-lasting than normal. The size of tendon jerks can be measured by either EMG response or by recordings of mechanical events. H-reflex studies are electrically elicited tendon jerks and are mainly restricted to the soleus and flexor carpi radialis muscles in normal adults. In cases of upper motor neuron lesions, the H-reflex may be elicited in muscles where it is not normally seen, such as the intrinsic hand muscles, tibialis anterior, or peroneal muscles (79). Neurophysiological studies, such as the H-reflex study, may be performed in patients with neurodegenerative disease.

Basic laboratory studies can help identify metabolic derangement. Enzymatic assays, EMG or nerve conduction study, and genetic testing can help identify neurodegenerative diseases or other genetic causes of neurologic abnormalities. A baseline EEG to establish underlying seizure activity can also be done to determine any seizure activity associated with the underlying condition.

Table 3. Useful Tests for Diagnosis

Test	Use
MRI of the brain and spine	Disorders of the central nervous system (periventricular leukomalacia, stroke, tumor)
Basic lab studies	Metabolic derangements
Enzymatic assay	Neurodegenerative diseases
Genetic workup (whole exome sequencing etc.)	Genetic causes of neurologic, neuromuscular, and musculoskeletal disorders
Muscle biopsy	Neuromuscular and muscular disorders
NCS/EMG	Neurodegenerative disease (leukodystrophies), identifying cause of neurologic symptoms such as weakness, or sensory disorders.
EEG	Underlying seizure activity

Management

Pharmacological management

Oral therapy. Oral medications can decrease spasticity; however, many have unwanted side effects, such as drowsiness, sedation, confusion, and fatigue.

Baclofen. Baclofen is a GABA-B agonist acting centrally in the brain and spinal cord. Baclofen binds with GABA-B receptors, restricting calcium influx into presynaptic nerve terminals, thereby reducing spasticity (19). The clinical effects include decreased resistance to passive motion, decreased hyperreflexia, and reduced painful spasms and clonus. Baclofen can be administered intrathecally and orally. When taken orally, it is absorbed in the upper small intestine. There is no rectal or colonic absorption. Due to the relatively small area for absorption, there is a potential for a saturation phenomenon to be observed, where escalating doses do not increase effectiveness after a certain point. Oral preparations include tablets, granules, and liquid suspension.

Tizanidine. Tizanidine is an alpha-2 adrenergic agonist acting centrally in the brain and spinal cord. It prevents the release of excitatory neurotransmitters (norepinephrine), resulting in reduced spasticity and hyperreflexia. Animal studies with tizanidine demonstrate antinociceptive activity under specific conditions with increased dose titration (10; 08; 69; 45). Potential side effects include drowsiness, dry mouth, weakness, hypotension, and elevation of liver function tests. Literature suggests that tizanidine may be better tolerated than other antispasticity agents as measured by the global tolerance rating scale (39). In placebo-controlled studies, tizanidine has been shown to be effective in multiple sclerosis and spinal cord injury. It is also helpful for spasticity of spinal pathology when weakness is of concern. Tizanidine may also prove effective in managing spasticity of cerebral origin (47). Monitoring of liver function is recommended with tizanidine use.

Clonidine. Clonidine belongs to the same class as tizanidine (alpha-2 adrenergic agonist), although clonidine has some alpha-1 agonist activity. Clonidine can be given orally and also transdermally. Hypotension is a potential side effect.

Dantrolene. Dantrolene is unique in that it acts peripherally at the muscle fiber level. It does not affect neuromuscular transmission but works by hindering calcium release from the sarcoplasmic reticulum, thereby preventing the excitation-contraction coupling mechanism. This affects both intrafusal and extrafusal fibers by decreasing the force of muscle contraction. This mechanism is not selective for muscles with increased tone, and generalized muscle weakness may result and could potentially weaken respiratory muscles. Dantrolene is indicated for treating spasticity secondary to cerebrovascular accident and cerebral palsy and has possible applications for traumatic brain injury, spinal cord injury, and multiple sclerosis. Clinical effects of dantrolene sodium include decreased resistance to passive range of motion, decreased hyperreflexia and tone, and reduced spasms and clonus. Like tizanidine, dantrolene can raise liver function tests and requires periodic monitoring of liver function.

Benzodiazepines. Benzodiazepines, such as diazepam, are not FDA-approved for spasticity but are commonly used. These authors do no generally recommend them as a first line due to their wide array of potential adverse effects as well as the potential for dependence. However, in children with cerebral palsy, diazepam, in particular, can be considered a first-line treatment (51). Benzodiazepines are effective in spinal cord injury, multiple sclerosis, cerebral palsy, and stroke-related spasticity. Benzodiazepines are generally avoided in traumatic brain injury due to cognitive side effects but can be useful in withdrawal from intrathecal baclofen scenarios. Clinical effects include sedation, reduced anxiety, decreased resistance to passive range of motion, decreased hyperreflexia, and reduced painful spasms. Side effects of all benzodiazepines include sedation, weakness, hypotension, gastrointestinal symptoms, memory impairment, incoordination, confusion, depression, and ataxia. Also, benzodiazepines are controlled substances with the potential for dependency. Diazepam is the most widely used benzodiazepine for spasticity management. If nocturnal spasticity is the presenting problem, the patient should be started with a single dose at night.

Secondary oral agents. Secondary oral agents include cyproheptadine, lamotrigine, and gabapentin (25). Additional studies have confirmed the benefit of gabapentin in multiple sclerosis (09) and spinal cord injury (28; 50; 55).

Cyproheptadine. Cyproheptadine is an antihistamine and a serotonin antagonist. Although not approved for spasticity, it has been described to be helpful with spasticity in patients with spinal cord injury or multiple sclerosis without side effects of weakness. Adverse effects include sedation and dry mouth.

Cannabis or cannabinoids. The active alkaloid of the cannabis plant is delta-9-tetrahydrocannabinol (THC). This is available as a dronabinol or as a synthetic cannabinoid nabilone. Although anecdotally reported to be associated with reducing spasticity in multiple sclerosis, stroke, and spinal cord injury, it has been studied more recently in patients with multiple sclerosis. In a meta-analysis of 14 studies with 2280 participants (2,138 with multiple sclerosis and 142 with spinal cord injury), cannabinoids were associated with improvements in spasticity, but this failed to reach statistical significance in most studies (72). There were no clear differences based on the type of cannabinoid. Only studies in patients with multiple sclerosis reported sufficient data to generate summary estimates. Cannabinoids (nabiximols, dronabinol, and THC/CBD) were associated with a greater average improvement on the Ashworth scale for spasticity compared with placebo, although this did not reach statistical significance.

Other muscle relaxants. Some drugs, such as cyclobenzaprine, metaxalone, and methocarbamol, are prescribed as skeletal muscle relaxants, but they have not been shown to be effective in spasticity. They are centrally acting, but the exact mechanism of action is poorly understood. They do not directly affect skeletal muscle, motor end plates, or peripheral nerves.

Intrathecal baclofen therapy. It has been established that oral baclofen has a limited area of absorption in the small intestine, does not effectively cross the blood-brain barrier (where it has its site of action in the GABA-B receptors of the brain and spinal cord), and is associated with serious side effects at higher doses (19). Intrathecal baclofen results in a greater decrease in spasticity by allowing higher concentrations of baclofen in the cerebrospinal fluid at about 1% of the daily oral dosage (32). Intrathecal baclofen therapy involves the infusion of baclofen from a pump implanted in the abdominal wall through a catheter that is surgically positioned in the intrathecal space. An external radiotelemetry hand-held device programs infusion settings. The intrathecal baclofen pump can be programmed to deliver baclofen continuously throughout the day or only during specific periods whenever the spasticity interferes with comfort or function (20).

Before implantation of an intrathecal baclofen pump, an intrathecal baclofen trial, in which a test dose of 50 to 100 µg of baclofen is delivered via lumbar puncture or spinal catheter, is recommended (20). After implantation, the pump is periodically refilled by percutaneous access to the central reservoir.

Intrathecal baclofen will circulate throughout the CSF but tends to affect muscles below the level of the catheter tip to a greater degree, often providing relatively more benefit to the lower limbs than the upper limbs. Intrathecal baclofen therapy can significantly improve function and quality of life and offers the most precise delivery control. Additionally, intrathecal baclofen therapy is cost-effective when one considers cumulative medical costs relative to anticipated costs without a pump implant (61).

Complications associated with intrathecal baclofen are rare but include pump mechanical failure, including rotor stall and battery failure, catheter migration or disruption, human errors such as programming or refill error, and surgical complications such as cerebrospinal fluid leakage, pump pocket seroma, hematoma, infection, and soft tissue erosion. Both abrupt withdrawal from intrathecal baclofen and overdose are life-threatening conditions that require immediate medical attention in the hospital setting. Best practice guidelines are available to guide the management of these conditions (62).

Intrathecal clonidine. Although clonidine's primary route of administration is oral or transdermal, there have been reports of its off-label use via intrathecal delivery to relieve spasticity. Case studies and reports have suggested that intrathecal clonidine, either used as single or adjuvant therapy, can modulate the transmission of pain signals by inhibiting the release of excitatory neurotransmitters. In one review, 24 patients received intrathecal clonidine for 5 or more years, with relief in spasticity and pain and no significant adverse effects (29). Another case described significant relief of anal sphincter spasms in a tetraplegic patient after clonidine was added to her intrathecal baclofen pump (48). In the event of withdrawal, management would include antihypertensive therapy and consideration of cardiac monitoring.

Pharmacologic focal treatments. There is no single algorithm for treatment of spasticity. Focal therapies are appropriate first-line therapies for focal problems, but a combination of therapies is often needed to achieve optimal results.

Focal therapy options for spasticity management can be divided broadly into pharmacologic and nonpharmacologic treatments. Pharmacologic options include chemoneurolysis with ethyl alcohol or phenol and chemodenervation with botulinum neurotoxin. Local anesthetic nerve blocks are sometimes used diagnostically as a prelude to additional treatments. An emerging but currently off-label pharmacologic focal therapy is the injection of hyaluronidase. Nonpharmacologic options include surgeries such as tendon lengthening, tendon transfers, tendon release, functional neurotomy, and nerve transfers. An emerging but currently off-label nonpharmacologic focal treatment for spasticity is cryoneurolysis.

Local anesthetic blocks. Local anesthetic blocks produce a temporary block via Na+ channel inactivation. Temporary nerve blocks with local anesthetic can distinguish the relative contribution of spasticity versus contracture. They can be useful to see what range is possible and determine whether additional procedures, such as chemodenervation, will effectively achieve the desired outcome. For instance, in severe spasticity, when passive movement is difficult or impossible, it can be challenging to determine if a joint is completely contracted or if the spasticity is too severe for the limb to be passively moved. A temporary block can paralyze the muscles innervated by the branch of the nerve block, allowing the examiner to determine how much range of motion a patient has if the spastic portion is removed. Local anesthetic nerve blocks are typically performed with bupivacaine, which has an onset of action of 5 to 10 minutes and a duration of 4 to 8 hours, or lidocaine, which has an onset of 1 to 2 minutes and a duration of 2 hours.

Chemoneurolysis. Chemoneurolysis is performed similarly to nerve blocks, except phenol or ethyl alcohol are used. Unlike the effects of local anesthetics, the effects of injection of phenol or ethyl alcohol are immediate and permanent. Proper training is necessary to perform this procedure safely. Nerves are localized through the use of electrical stimulation (76; 19). The nerve and surrounding supportive connective tissue structures are lysed by protein denaturation, but sprouting and regeneration can ultimately allow the recurrence of muscle overactivity, necessitating repeating the procedure in the future, often months to years later.

If neurolysis is performed on whole nerves, both afferent and efferent fibers will be disrupted. All muscles innervated by that nerve will be paralyzed, and anesthesia will occur in the skin supplied by the sensory branches. Incomplete lysis of sensory fibers can result in painful dysesthesias. Neurolysis can also be performed on motor branches, which is more selective (49). With selective motor branch neurolysis, dysesthesias are rare.

Chemodenervation. Chemodenervation with botulinum neurotoxin is a first-line option for focal treatment of spasticity. First clinically introduced in the United States in the early 1980s, botulinum neurotoxin is derived from the anaerobic bacteria Clostridium botulinum, the same organism responsible for botulism. There are seven serotypes of botulinum neurotoxin, types A, B, C, D, E, F, and G, but only types A and B are commercially available in the United States. Other serotypes are available in Europe.

Botulinum neurotoxin is delivered to spastic muscles via percutaneous injection and is then taken up into the axon terminal, where it has its site of action. Botulinum neurotoxin works by cleaving the SNARE proteins, which allow the synaptic vesicles containing acetylcholine to fuse with the membrane of the axon terminal to release acetylcholine into the neuromuscular junction. Botulinum neurotoxin type A cleaves the SNARE protein SNAP-25, and botulinum neurotoxin type B cleaves the SNARE protein synaptobrevin. Individual brands may vary, but botulinum neurotoxin types A and B reach peak effectiveness by about 2 weeks post-injection and last approximately 12 weeks.

Effects are reversible, and patients who enjoy the effects of botulinum neurotoxin will require re-injection once the effects wear off. The main potential side effect is weakness. Adverse effects are not common and are usually associated with the site of injection, such as bleeding, bruising, injection site soreness, or diffusion to nearby muscle groups. Botulinum neurotoxin is contraindicated during pregnancy, lactation, and in individuals with known allergies to the drug. Caution is advised in patients with neuromuscular junction disorders, such as myasthenia gravis, and in patients taking certain drugs that could potentiate the effects, such as aminoglycoside antibiotics or paralytic agents (eg, vecuronium). Though poorly studied, long-term use of chemodenervation has been linked to muscle atrophy, which may be related to toxin serotype, lipid accumulation, changes in blood flow, mitochondrial dysfunction, and muscle fiber type (60). Using injection guidance, such as EMG amplifier guidance, electrical stimulation, ultrasound, or a combination of these methods, is recommended with strong evidence (27). Dosing is based on the muscle size and its relative involvement in the spastic position, and dosing guidelines are available for each commercially available botulinum neurotoxin agent.

Hyaluronidase. Hyaluronidase injection is an emerging and off-label treatment for spasticity, which targets muscle's abnormal elasticity (stiffness) (57). The theory behind its effectiveness is that paralysis and immobility lead to atrophy of muscle fibers, a relative increase in the extracellular matrix, and an increase in hyaluronan. At high concentrations, hyaluronan can dramatically increase the viscosity of the extracellular matrix and decrease the sliding of muscle fibers, leading to shortening and fibrosis of muscles. In a study of spastic muscles of the upper limbs of 20 patients, 75 units of hyaluronidase were injected per site, up to 600 units. This intervention was paired with exercise, and a resultant increased range of motion was observed, which persisted for at least 3 months (57).

Nonpharmacological management

Therapies. Therapies are fundamental to gaining strength, maintaining and increasing range of motion, and, most importantly, improving function. Although it does not seem to affect spasticity directly, it is a critical part of treating people with spasticity (35; 51). There are many beneficial therapies, including muscle strengthening and stretching, the practice of functional tasks, sensory integration, targeted muscle training, constraint-induced movement therapy, treadmill training, aqua therapy, and hippotherapy. Many more therapies exist that improve function and quality of life in individuals with spasticity.

Modalities, alternative medicine, and stem cell treatments. A systematic review of the nonpharmacologic treatment of spasticity for adults concluded that there was moderate evidence for electroacupuncture combined with conventional routine care (pharmacological or rehabilitation) (35). Evidence also shows that traditional acupuncture decreases spasticity (51). The mechanism is unknown, but theories with limited studies include that acupuncture or electroacupuncture may break the pain-spasm-pain cycle, decrease the hyperexcitability of gamma and alpha motor neurons or increase the inhibition of interneurons, or increase GABA levels and decrease levels of excitatory neurotransmitters in the brain and spinal cord (81). There is also moderate evidence for neuromuscular electric stimulation combined with other interventions (35).

There is some low-quality evidence for extracorporeal shock wave therapy, transcranial direct current stimulation for stroke, and transcranial magnetic stimulation and transcutaneous electrical nerve stimulation for other neurologic conditions, as well as repetitive magnetic stimulation in multiple sclerosis and vibration therapy (35). Further studies are needed to understand the effect of these interventions on spasticity; however, they show some promise in the temporary relief of spasticity.

A systematic review showed some support for increased objective measures of spasticity with pregnancy, posture, cold, circadian rhythm, and skin conditions (54). Additionally, increased self-reports of spasticity included bowel- and bladder-related issues, menstrual cycle, mental stress, and tight clothing (54).

Hyperbaric oxygen does not treat spasticity, nor has it shown functional benefits for patients with spasticity (07; 51).

Looking to the future, stem cell therapy shows promise in treating various central nervous system conditions causing spasticity, but more research is needed (17; 42; 53; 80).

Cryoneurolysis. Cryoneurolysis is an emerging treatment for focal spasticity (73). Presently, cryoneurolysis is FDA-approved for pain but is currently off-label for spasticity. Unlike chemoneurolysis with phenol, which is not selective to neural tissue and destroys surrounding connective tissue, cryoneurolysis selectively targets neural tissue, causing Wallerian degeneration. As the surrounding connective tissue is not lysed, cryoneurolysis is potentially safer than chemoneurolysis (06; 31; 73), and subsequent procedures performed in the same area, should spasticity recur, are said to be less technically challenging in terms of nerve localization than they are with repeat chemoneurolysis.

Surgical interventions. Surgical interventions include peripheral procedures (rhizotomy, neurectomies, stereotactic radiosurgery) and central procedures (cordectomy, myelotomy, or cerebellar or spinal electrode stimulators) as well as combined surgical and pharmacological treatment of intrathecal baclofen pump discussed above.

There is the most evidence for selective dorsal rhizotomy, especially in children with cerebral palsy, which will be covered in detail below. There is also some evidence for the success of selective neurectomy (26; 40; 44). For severe, intractable cases of spasticity, there have been some papers looking at the use of cordectomies (37) and myelotomies (65; 43) as well as some experimentation on stereotactic radiosurgery of peripheral nerves (56). Implantation of cerebellar or spinal stimulators (66) and deep brain stimulators may show some benefit for spasticity, although more research is needed.

Nerve transfer to improve spasticity and function also shows promise. One randomized control trial studied the effect of a C7 nerve transfer from the unaffected side to the affected spastic arm from chronic cerebral injury (78). Significant improvements in power, function, and reduced spasticity at 12 months post-surgery were seen compared to the control group that only received physical therapy.

Selective dorsal rhizotomy. Selective dorsal rhizotomy is a treatment used to alleviate spasticity, specifically in children with cerebral palsy. Generally, this is best performed between the ages of 3 and 10 years to treat a patient before they develop joint contractures or hip subluxation or dislocation while simultaneously waiting until they are mature enough to participate in inpatient rehabilitation therapy after selective dorsal rhizotomy (22). Factors that make a child a good candidate for selective dorsal rhizotomy include having a General Motor Functional Classification System (GMFCS) I, II, and II, spastic diplegia, and gross motor function measure (GMFM) over 60 (15). Poor candidates are patients with poor motor control, those who depend on their spasticity for function due to underlying weakness, and those with underlying dystonia. This neurosurgery is meticulous and generally requires a neurophysiologist and a physiatrist or therapist to help identify the the percentage of nerve rootlets and which nerve root levels are to be severed based on the degree and location of spasticity limiting function. Studies have shown that performing selective dorsal rhizotomy at a young age can reduce the need for orthopedic surgery and botox injections (15). Side effects include sensory deficits and bladder incontinence (34). There also may be an increased risk of scoliosis and lordosis an average of 4 to 11 years after selective dorsal rhizotomy (68; 33).

A summary of spasticity interventions is provided in Table 4.

Treatment of contractures. The best treatment is the prevention of contractures via treating spasticity (as outlined above) and regular stretching of joints via therapies, bracing, splints, and all movement activities. Most contractures can be prevented when treatments are started immediately after spasticity starts, which is why early identification and treatment are critical. Once contractures have developed, the main treatments are serial casting and orthopedic procedures.

Serial casting. Serial casting, where a cast is placed on a joint and replaced weekly, each time intensifying the stretch, has been shown to be beneficial for increasing the range of motion. Serial casting combined with botulinum toxin injections is the gold standard for contracture treatment in children with cerebral palsy (51) and has also shown to be successful in adult patients with spasticity, including stroke and brain injury (74; 41). Serial casting is generally started about 1 to 2 weeks after botox is given to maximize the benefits of botox in facilitating the stretch achieved during serial casting and tolerance. Serial casting can also be done without botulinum toxin. Most commonly, the ankle joint is done, and weight bearing is allowed while in the cast.

Orthopedic procedures for contractures. Orthopedic procedures are performed for contractures not responsive to more conservative measures restricting function or quality of life. The targets of these operations are tendons or bones. Muscle tendons may be released, lengthened, or transferred. The goals of surgery are to increase the range of motion, improve access for hygiene, improve the ability to tolerate braces, or reduce pain.

Tendon release. In this procedure, the tendon of a muscle that has a contracture is partially or completely cut. The joint is then positioned at a more normal angle, and a cast is applied. Regrowth of the tendon to a new length occurs over several weeks. Another example of a tendon release surgery is an operation known as a slide procedure used to lengthen the supraspinatus muscle in a shoulder abduction contracture. The surgeon can release all four muscles that typically cause this deformity.

Tendon transfer. A tendon from a spastic muscle is cut and then transferred to a different site, changing the direction that the joint is pulled. In some situations, the transfer allows improved function. In others, the joint retains passive but not active function. Ankle-balancing procedures are among the most effective interventions.

Osteotomy. In an osteotomy, a small wedge is removed from a bone to allow it to be repositioned or reshaped. It is often accompanied by operations to lengthen or split tendons to allow for fuller correction of the joint deformity. A cast is applied while the bone heals in a more natural position. Osteotomy procedures are commonly used to correct hip subluxation or dislocation and foot deformities.

Arthrodesis. In arthrodesis, bones are fused to limit movement. This fusion limits the ability of a spastic muscle to pull the joint into an abnormal position but also prevents joint movements. This is done when the spastic pull of a muscle on the bone cannot be controlled, and it is deemed best to prevent movement at the joint to attain functional or preventative goals. Most often, arthrodesis is performed on the ankle and foot. In triple arthrodesis, the three joints of the foot are exposed, the cartilage is removed, and screws are inserted into the bones, fixing the joints into position. With a short walking cast in place for 6 weeks or until the bones have fully healed, the patient may bear weight immediately after the operation (WE MOVE 2007).

Special considerations in children. Other principal treatments in children with cerebral palsy include single-event multilevel surgery, where multiple orthopedic surgeries are combined into one and carefully planned and timed, given that children are growing.

Table 4. Therapeutic Interventions for Spasticity

Therapeutic intervention	Mechanisms	Major points
Pharmacologic treatments
Oral pharmacologic treatments
Baclofen	GABA-B agonist, centrally acting. Restricts calcium influx into presynaptic nerve terminals.	Absorbed in the upper small intestine with potential for saturation phenomenon. Signs of withdrawal include pruritus, irritation, and increased spasms.
Tizanidine	Alpha-2 adrenergic agonist, centrally acting. Inhibits spinal reflex arc by preventing the release of excitatory neurotransmitters.	Side effects of sedation, hypotension/dizziness, xerostomia. Hepatic clearance and LFT monitoring are recommended.
Clonidine	Alpha-2 adrenergic agonist, some alpha-1 agonist activity.	Side effect of hypotension. Available in oral or transdermal formulations.
Dantrolene	Ryanodine receptor agonist, peripherally acting at muscle fibers. Inhibits calcium release from the sarcoplasmic reticulum.	Hepatic clearance and LFT monitoring are recommended. Potential side effects are hepatotoxicity and respiratory muscle weakness.
Benzodiazepines	GABA-A agonist, centrally active. Increases chloride influx into presynaptic nerve terminals.	Not FDA-approved for spasticity. Strong sedating effect and potential dependence. Avoided in traumatic brain injury due to cognitive side effects. Can be useful in treating intrathecal baclofen withdrawal.
Cyproheptadine	Antihistamine and serotonin antagonist.	Not approved for spasticity. May be helpful in patients with spinal cord injury or multple sclerosis without the side effect of weakness.
Cannabis or cannabinoids	Increased activation of GABAergic inhibitory interneurons	Anecdotally reported to be associated with reducing spasticity but not yet statistically significant in studies.
Muscle relaxants: cyclobenzaprine, metaxalone, methocarbamol	Centrally acting; exact mechanism is poorly understood.	No direct action on skeletal muscle, motor end plates, or peripheral nerves
Focal pharmacologic treatments
Chemoneurolysis	Nerves localized via e-stim. Phenol or ethyl alcohol used to lyse nerve and surrounding connective tissue.	Effects are immediate and permanent, though sprouting may necessitate a repeat procedure (months-years). Painful dysesthesias if incomplete lysis of sensory fibers. Rare with selective motor branch neurolysis.
Chemodenervation	Botulinum toxin cleaves SNARE proteins, preventing release of acetylcholine into the neuromuscular junction.	Effects are reversible with protein regeneration. Requires regular re-injection. Primary side effect is weakness. Use of injection guidance recommended (EMG, e-stim, US).
Hyaluronidase	Theorized to decrease hyaluronan in order to decrease viscosity of extracellular matrix and increase sliding of muscle fibers	Emerging and off-label treatment
Intrathecal pharmacologic treatments
Intrathecal baclofen therapy	Infusion of baclofen from pump implanted in abdominal wall through a catheter surgically positioned in the intrathecal space	Damage to sensory and motor nerves, painful dysesthesias
Nonpharmacologic treatments
Surgical treatments
Selective dorsal rhizotomy	Balancing spinal cord-mediated facilitatory and inhibitory control	Permanent effect. Can result in excessive hypotonia.
Nerve transfer	Providing innervation to muscles with spastic paralysis	Initial studies show improvement in strength, spasticity, and function.
Other
Cryoneurolysis	Selectively targets neural tissue causing Wallerian degeneration.	Emerging treatment. FDA-approved for pain but off-label for spasticity. Unlike chemoneurolysis, it preserves surrounding connective tissue and is less technically challenging.
Acupuncture and electro-acupuncture	Mechanism unknown at this time. Several theories exist.	Evidence for improvement when combined with pharmacological and rehabilitation treatments.
Neuromuscular electric stimulation	Mechanism unknown at this time. Several theories exist.	Evidence for improvement when combined with pharmacological and rehabilitation treatments.
Treatments for contractures
Physical and occupational therapy	Stretching exercises anywhere from once daily to several times per day, practice of functional tasks	Limited effect on the patient's spasticity; however, critical treatment for functional benefits as well as contracture prevention.
Serial casting, splints, and bracing	Sustained stretch over time stretches soft tissue. Serial casting provides an intensive progressive stretch.	Splints and bracing can be used to slow down or prevent contractures, whereas serial casting can be used to treat contractures. Best results of serial casting in conjunction with botulinum toxin.
Orthopedic surgery: tendon release, tendon transfer, osteotomy, arthrodesis	Surgically correct contracture and/or improve joint position.	Functional goals should be chosen pre-operatively. Care in selection of surgical intervention as well as timing, especially in growing children.

Media

References

01: Abbott R. Sensory rhizotomy for the treatment of childhood spasticity. J Child Neurol 1996;11(suppl 1):S36-42. PMID 8959460
02: Adams MM, Hicks AL. Spasticity after spinal cord injury. Spinal Cord 2005;43(10):577-86. PMID 15838527
03: Albright AL. Spasticity and movement disorders in cerebral palsy. J Child Neurol 1996;11(suppl 1):S1-4. PMID 8959455
04: Anonymous. Spinal Cord Injury (SCI) 2016 Facts and Figures at a Glance. J Spinal Cord Med 2016;39(4):493-4. PMID 27471859
05: Bohannon RW, Smith MB. Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther 1987;67(2):206-7. PMID 3809245
06: Cheng J, Hu R, Wang Q, et al. Substrate temperature effect on charge transport performance of ZnO electron transport layer prepared by a facile ultrasonic spray pyrolysis in polymer solar cells. Int J Photoenergy 2015;2015:1-8.
07: Collet JP, Vanasse M, Marois P, et al. Hyperbaric oxygen for children with cerebral palsy: a multicenter, placebo controlled, randomised clinical trial. Lancet 2001;357:582-6. PMID 11558483
08: Coward DM, Emre M. Myotonolytic and antinociceptive properties of Sirdalud in animals and man. In: Emre M, Mathies H, editors. Muscle spasms and pain. Camforth, UK: Parthenon, 1988:101-9.
09: Cutter NC, Scott DD, Johnson JC, Whiteneck G. Gabapentin effect on spasticity in multiple sclerosis: a placebo-controlled, randomized trial. Arch Phys Med Rehabil 2000;81(2):164-9. PMID 10668769
10: Davies J, Johnston SE. Selective antinociceptive effects of tizanidine (DS 103-282), a centrally acting muscle relaxant, on dorsal horn neurones in the feline spinal cord. Br J Pharmcol 1984;82:409-21. PMID 6733365
11: DeLisa JA, Gans BM, Walsh NE, Bockneck WL, Frontera WR. Physical medicine and rehabilitation: principles and practice. Philadelphia: Lippincott Williams & Wilkins, 2004.
12: Dimitrijevic MR. Clinical assessment of spasticity. In: Neurosurgery for spasticity: a multidisciplinary approach. New York: Springer-Verlag, 1991:33-7.
13: Dobkins BH. The clinical science of neurologic rehabilitation. London: Oxford University Press, 2003.
14: Drew LB, Drew WE. The contrecoup-coup phenomenon: A new understanding of the mechanism if closed head injury. Neurocrit Care 2004;1(3):385-90. PMID 16174940
15: Dudley RW, Parolin M, Gagnon B, et al. Long-term functional benefits of selective dorsal rhizotomy for spastic cerebral palsy. J Neurosurg Pediatr 2013;12(2):142-50. PMID 23713680
16: Elovic E, Zafonte RD. Spasticity management in traumatic brain injury. State Art Rev Rehabil 2001;15(2):327-48.
17: Ejma M, Madetko N, Brzecka A, et al. The role of stem cells in the therapy of stroke. Curr Neuropharmacol 2022;20(3):630-647. PMID 34365923
18: Filloux FM. Neuropathophysiology of movement disorders in cerebral palsy. J Child Neurol 1996;(suppl 1):S5-12. PMID 8959456
19: Francisco GE, Ivanhoe CB. Pharmacologic management of spasticity in adults with brain Injury. In: Kraft GH, Horn LJ, editors. Physical medicine and rehabilitation 8:4. Philadelphia: WB Saunders Company, 1997:707-31.
20: Francisco GE, Saulino MF, Yablon SA, Turner M. Intrathecal baclofen therapy: an update. PM R 2009;1(9):852-8. PMID 19769920
21: Frerebeau PH, Segnarbieux F, Ohanna F, Ronzier JF. Clinical feature of spasticity. In: Neurosurgery for spasticity: a multidisciplinary approach. New York: Springer-Verlag, 1991:29-32.
22: Graham D, Aquilina K, Mankad K, Wimalasundera N. Selective dorsal rhizotomy: current state of practice and the role of imaging. Quant Imaging Med Surg 2018;8(2):209-18. PMID 29675362
23: GBD 2019 Stroke Collaborators. Global, regional, and national burden of stroke and its risk factors, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Neurol 2021;20(10):795-820. PMID 34487721
24: Georges A, Das MJ. Traumatic brain injury. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing, 2023.
25: Gracies JM, Nance P, Elovic E, et al. Traditional pharmacological treatments for spasticity part II: general and regional treatments. Muscle Nerve 1997;20(suppl 6):S92-120. PMID 9826984
26: Gras M, Leclercq C. Spasticity and hyperselective neurectomy in the upper limb. Hand Surg Rehabil 2017;36(6):391-401. PMID 29033227
27: Grigoriu AI, Dinomais M, Rémy-Néris O, Brochard S. Impact of injection-guiding techniques on the effectiveness of botulinum toxin for the treatment of focal spasticity and dystonia: a systematic review. Arch Phys Med Rehabil 2015;96(11):2067-78.e1. PMID 25982240
28: Gruenthal M, Mueller M, Olson WL, Priebe MM, Sherwood AM, Olson WH. Gabapentin for the treatment of spasticity in patients with spinal cord injury. Spinal Cord 1997;35(10):686-9. PMID 9347598
29: Ho JK, Sadiq SA. Use of intrathecal clonidine in patients with multiple sclerosis or spastic paraparesis. J Neurol 2012;259(5):982-4. PMID 22057402
30: Hughes C, Howard IM. Spasticity management in multiple sclerosis. Phys Med Rehabil Clin N Am 2013;24(4):593-604. PMID 24314678
31: Ilfeld BM, Preciado J, Trescot AM. Novel cryoneurolysis device for the treatment of sensory and motor peripheral nerves. Expert Rev Med Devices 2016;13(8):713-25. PMID 27333989
32: Im D, McDonald CM. New approaches to managing spasticity in children with cerebral palsy. West J Med 1997;166(4):271. PMID 9168686
33: Johnson M, Goldstein L, Thomas SS, Piatt J, Aiona M, Sussman M. Spinal deformity after selective dorsal rhizotomy in ambulatory patients with cerebral palsy. J Pediatr Orthop 2004;24(5):529-36. PMID 15308903
34: Kakodkar P, Girgis H, Nabhan P, Chee SS, Tu A. Efficacy of selective dorsal rhizotomy and intrathecal baclofen pump in the management of spasticity. Adv Tech Stand Neurosurg 2022;45:379-403. PMID 35976458
35: Khan F, Amatya B, Bensmail D, Yelnik A. Non-pharmacological interventions for spasticity in adults: an overview of systematic reviews. Ann Phys Rehabil Med 2019;62(4):265-73. PMID 29042299
36: Koman LA, Mooney JF, Smith BP. Neuromuscular blockage in the management of cerebral palsy. J Child Neurol 1996;11(suppl1):S23-8. PMID 8959458
37: Konar SK, Maiti TK, Bir SC, Nanda A. Spinal cordectomy: a new hope for morbid spinal conditions. Clin Neurol Neurosurg 2017;152:5-11. PMID 27846400
38: Lance JW. The control of muscle tone, reflexes, and movement: Robert Wartenberg Lecture. Neurology 1980;30(12):1303-13. PMID 7192811
39: Lataste X, Emre M, Davis C, Groves L. Comparative profile of tizanidine in the management of spasticity. Neurology 1994;44(suppl 9):53-9. PMID 7970011
40: Leclercq C, Perruisseau-Carrier A, Gras M, Panciera P, Fulchignoni C, Fulchignoni M. Hyperselective neurectomy for the treatment of upper limb spasticity in adults and children: a prospective study. J Hand Surg Eur Vol 2021;46(7):708-16. PMID 34256619
41: Leung J, King C, Fereday S. Effectiveness of a programme comprising serial casting, botulinum toxin, splinting and motor training for contracture management: a randomized controlled trial. Clin Rehabil 2019;33(6):1035-44. PMID 30813776
42: Li X, Sundstrom E. Stem cell therapies for central nervous system trauma: the 4 ws-what, when, where, and why. Stem Cells Transl Med 2022;11(1):14-25. PMID 35641168
43: Livshits A, Rappaport ZH, Livshits V, Gepstein R. Surgical treatment of painful spasticity after spinal cord injury. Spinal Cord 2002;40(4):161-6. PMID 11965553
44: Mahan MA, Eli I, Hamrick F, et al. Highly selective partial neurectomies for spasticity: a single-center experience. Neurosurgery 2021;89(5):827-35. PMID 34382654
45: McCarthy RJ, Kroin JS, Lubenow TR, Penn RD, Ivankovich AD. Effect of intrathecal tizanidine on antinociception and blood pressure in the rat. Pain 1990;40(3):333-8. PMID 2326097
46: McGuire JR. Epidemiology of spasticity in the adult and child. In: Brashear A, Elovic E, editors. Spasticity: Diagnosis and Management. 1st ed. Demos Medical Publishing, 2011:5-15.
47: Medici M, Pebet M, Ciblis D. A double-blind, long-term study of tizanidine ('Sirdalud') in spasticity due to cerebrovascular lesions. Curr Med Res Opin 1989;11(6):398-407. PMID 2651016
48: Middleton JW, Siddall PJ, Walker S, Molloy AR, Rutkowski SB. Intrathecal clonidine and baclofen in the management of spasticity and neuropathic pain following spinal cord injury: a case study. Arch Phys Med Rehabil 1996;77(8):824-6. PMID 8702379
49: Mulhern J, Gupta S, Heckert K. Diagnostic anesthetic blocks: differentiating contracture from spasticity. In: Handbook of Spasticity. Demos Medical Publishing: Philadelphia, 2023.
50: Mueller ME, Gruenthal M, Olson WL, Olson WH. Gabapentin for relief of upper motor neuron symptoms in multiple sclerosis. Arch Phys Med Rehabil 1997;78(5):521-4. PMID 9161373
51: Novak I, Morgan C, Fahey M, et al. State of the Evidence Traffic Lights 2019: systematic review of interventions for preventing and treating children with cerebral palsy. Curr Neurol Neurosci Rep 2020;20(2):3. PMID 32086598
52: Patejdl R, Zettl UK. Spasticity in multiple sclerosis: contribution of inflammation, autoimmune mediated neuronal damage and therapeutic interventions. Autoimmun Rev 2017;16(9):925-36. PMID 28698092
53: Peterson S, Jalil A, Beard K, Kakara M, Sriwastava S. Updates on efficacy and safety outcomes of new and emerging disease modifying therapies and stem cell therapy for multiple sclerosis: a review. Mult Scler Relat Disord 2022;68:104125. PMID 36057173
54: Phadke CP, Balasubramanian CK, Ismail F, Boulias C. Revisiting physiologic and psychologic triggers that increase spasticity. Am J Phys Med Rehabil 2013;92(4):357-69. PMID 23620900
55: Priebe MM, Sherwood AM, Graves DE, Mueller M, Olson WH. Effectiveness of gabapentin in controlling spasticity: a quantitative study. Spinal Cord 1997;35(3):171-5. PMID 9076868
56: Romanelli P, Beltramo G. Image-guided stereotactic radiosurgery for the treatment of spasticity and pain: a preliminary experience. Cureus 2022;14(4):e24021. PMID 35463564
57: Raghavan P, Lu Y, Mirchandani M, Stecco A. Human recombinant hyaluronidase injections for upper limb muscle stiffness in individuals with cerebral injury: a case series. EBioMedicine 2016;9:306-13. PMID 27333050
58: Rizzo MA, Hadjimichael OC, Preiningerova J, Vollmer TL. Prevalence and treatment of spasticity reported by multiple sclerosis patients. Mult Scler 2004;10(5):589-95. PMID 15471378
59: Sadowska M, Sarecka-Hujar B, Kopyta I. Cerebral palsy: current opinions on definition, epidemiology, risk factors, classification and treatment options. Neuropsychiatr Dis Treat 2020;16:1505-18. PMID 32606703
60: Salari M, Sharma S, Jog MS. Botulinum toxin induced atrophy: an uncharted territory. Toxins (Basel) 2018;10(8):313. PMID 30072597
61: Saulino M, Guillemette S, Leier J, Hinnenthal J. Medical cost impact of intrathecal baclofen therapy for severe spasticity. Neuromodulation 2015;18(2):141-9. PMID 25145312
62: Saulino M, Anderson DJ, Doble J, et al. Best practices for intrathecal baclofen therapy: troubleshooting. Neuromodulation 2016;19(6):632-41. PMID 27434299
63: Shepherd E, Salam RA, Middleton P, et al. Neonatal interventions for preventing cerebral palsy: an overview of Cochrane Systematic Reviews. Cochrane Database Syst Rev 2018;6(6):CD012409. PMID 29926474
64: Shepherd E, Salam RA, Middleton P, et al. Antenatal and intrapartum interventions for preventing cerebral palsy: an overview of Cochrane systematic reviews. Cochrane Database Syst Rev 2017;8(8):CD012077. PMID 28786098
65: Sitthinamsuwan B, Khampalikit I, Phonwijit L, Nitising A, Nunta-Aree S, Suksompong S. Dorsal longitudinal T-myelotomy (Bischof II technique): a useful, antiquated procedure for the treatment of intractable spastic paraplegia. World Neurosurg 2018;116:e476-84. PMID 29753900
66: Smyth MD, Peacock WJ. The surgical treatment of spasticity. Muscle Nerve 2000;23(2):153-63. PMID 10639605
67: Tardieu G, Shentoub S, Delarue R. A la recherche d'une technique de mesure de la spasticité [Research on a technic for measurement of spasticity]. Rev Neurol (Paris) 1954;91(2):143-4. French. PMID 14358132
68: Turi M, Kalen V. The risk of spinal deformity after selective dorsal rhizotomy. J Pediatr Orthop 2000;20(1):104-7. PMID 10641698
69: Villanueva L, Chitour D, LeBars D. Effects of tizanidine (DS 103-282) on dorsal horn convergent neurones in the rat. Pain 1988;35:187-97. PMID 3237432
70: Walton C, King R, Rechtman L, et al. Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition. Mult Scler 2020;26(14):1816-21. PMID 33174475
71: WE MOVE. Worldwide Education and Awareness for Movement Disorders. Orthopedic operations. Available at: http://wemove.org/spa/spaoss.html. Accessed October 11, 2007.
72: Whiting PF, Wolff RF, Deshpande S, et al. Cannabinoids for medical use: a systematic review and meta-analysis. JAMA 2015;313(24):2456-73. PMID 26103030
73: Winston P, Mills PB, Reebye R, Vincent D. Cryoneurotomy as a percutaneous mini-invasive therapy for the treatment of the spastic limb: case presentation, review of the literature, and proposed approach for use. Arch Rehabil Res Clin Transl 2019;1(3-4):100030. PMID 33543059
74: Yasar E, Tok F, Safaz I, Balaban B, Yilmaz B, Alaca R. The efficacy of serial casting after botulinum toxin type A injection in improving equinovarus deformity in patients with chronic stroke. Brain Inj 2010;24(5):736-9. PMID 20334469
75: Yeargin-Allsopp M, Braun KV, Doernberg NS, Benedict RE, Kirby RS, Durkin MS. Prevalence of cerebral palsy in 8-year-old children in three areas of the united states in 2002: a multisite collaboration. Pediatrics 2008;121:547-54. PMID 18310204
76: Young RR. Spasticity: a review. Neurology 1994;44(suppl 9):S12-20. PMID 7970006
77: Zeng H, Chen J, Guo Y, Tan S. Prevalence and risk factors for spasticity after stroke: a systematic review and meta-analysis. Front Neurol 2021;11:616097. PMID 33551975
78: Zheng MX, Hua XY, Feng JT, et al. Trial of contralateral seventh cervical nerve transfer for spastic arm paralysis. N Engl J Med 2018;378(1):22-34. PMID 29262271
79: Zidar J, Dimitrijevi MR. In: Neurosurgery for spasticity: a multidisciplinary approach. New York: Springer-Verlag, 1991:39-46.
80: Zipser CM, Cragg JJ, Guest JD, et al. Cell-based and stem-cell-based treatments for spinal cord injury: evidence from clinical trials. Lancet Neurol 2022;21(7):659-70. PMID 35569486
81: Zhu Y, Yang Y, Li J. Does acupuncture help patients with spasticity? A narrative review. Ann Phys Rehabil Med 2019;62(4):297-301. PMID 30408516

Contributors

All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.

Authors

Hannah Aura Shoval MD

Dr. Shoval of Atlantic Health System’s Goryeb Children’s Hospital has no relevant financial relationships to disclose.
See Profile
Kimberly Heckert MD

Dr. Heckert of Thomas Jefferson University received speaker and consulting fees from AbbVie, Ipsen, and Merz Therapeutics.
See Profile
Elaine Hatch MD

Dr. Hatch of Thomas Jefferson University Hospital has no relevant financial relationships to disclose.
See Profile

Editor

Bernard L Maria MD

Dr. Maria of Thomas Jefferson University has no relevant financial relationships to disclose.
See Profile

Former Authors

Kimon Bekelis MD
Robert J Singer MD
Sarah Smathers BA, Hassan Tayem MD, Yasser Awaad MD, and Tamer Rizk MD

Patient Profile

Age range of presentation: 0 month to 65+ years
Sex preponderance: male=female
Heredity: Heredity may be a factor
Population groups selectively affected: none selectively affected
Occupation groups selectively affected: none selectively affected

This is an article preview.
Start a Free Account
to access the full version.

Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com

ISSN: 2831-9125

Spasticity

Associated Disorders

Adrenoleukodystrophy
Anoxia
Cerebral palsy
Multiple sclerosis
Neurodegenerative disease
- Spinal cord injury
- Stroke
- Traumatic brain injury

Differential Diagnosis

Rigidity
dystonia
guarding
hypertonia

Also Relevant

Acupuncture
Cerebral palsy
Childhood ataxia with central nervous system hypomyelination
Childhood movement disorders
Neurodegeneration with brain iron accumulation
- Hyperargininemia
- Hyperbaric oxygenation for the treatment of stroke
- Machado-Joseph disease
- Multiple sclerosis: presentation and course
- Nonautosomal dominant inherited ataxias
- Sjögren-Larsson syndrome

Clinical Categories

Patient Handouts

Web References

Guidelines

AAN: Pharmacologic treatment of spasticity in children and adolescents with cerebral palsy

Spasticity

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Table 1. The Modified Ashworth Scale

Table 2. Tardieu scale

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Epidemiology

Prevention

Differential diagnosis

Confusing conditions

Associated or underlying disorders

Diagnostic workup

Table 3. Useful Tests for Diagnosis

Management

Pharmacological management

Nonpharmacological management

Table 4. Therapeutic Interventions for Spasticity

Special considerations

Pregnancy

Media

References

Contributors

Authors

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview. Start a Free Account to access the full version.

Questions or Comment?

Also in This Category

NF2-related schwannomatosis

Neurogenetics and genetic and genomic testing

Acute traumatic spinal cord injury

Tumors of the skull base

Breath-holding spells

Toxic and nutritional deficiency optic neuropathies

Third nerve palsy

Nystagmus

This is an article preview.
Start a Free Account
to access the full version.